等待名单上的肾衰竭患者接受移植与继续等待的生存比较:系统综述与荟萃分析
该系统综述与荟萃分析检索了截至2021年3月1日的多个数据库,纳入48项观察性研究(n=1 245 850例患者),比较等待名单上肾衰竭患者接受移植与透析的生存获益。92%(44/48)的研究报告移植与透析相比具有长期生存获益,但其中11项研究报告了移植无统计学显著获益的亚组。18项适合荟萃分析的研究显示移植有生存获益(HR 0.45,95%CI 0.39-0.54;P<0.001),但存在显著异质性。
要点
- 92%(44/48)的观察性研究报告移植较透析有长期生存获益。
- 11项研究报告了移植无统计学显著生存获益的亚组。
- 荟萃分析显示移植有生存获益(HR 0.45,95%CI 0.39-0.54;P<0.001),但存在显著异质性。
核心结论
- 肾移植仍是大多数肾衰竭患者降低全因死亡率的更优治疗方式,但部分亚组可能缺乏生存获益。
- 鉴于供体器官持续稀缺,需要进一步证据以更好地为肾衰竭患者的决策提供信息。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Ovid Embase、Web of Science、Cochrane Collection和ClinicalTrials.gov,检索时间从数据库建库至2021年3月1日。
- 纳入所有比较等待名单上肾衰竭患者接受移植与透析的全因死亡率的对比研究。
- 共纳入48项观察性研究,无随机对照试验,n=1 245 850例患者。
- 由两名独立评审员提取数据并评估纳入研究的偏倚风险。
- 荟萃分析采用DerSimonian-Laird随机效应模型,通过亚组分析、敏感性分析和荟萃回归探究异质性。
主要发现
- 92%(44/48)的研究报告移植与透析相比具有长期(至少一年)生存获益。
- 11项研究报告了移植与继续等待相比无统计学显著获益的亚组。
- 18项适合荟萃分析的研究中,肾移植显示生存获益(HR 0.45,95%CI 0.39-0.54;P<0.001)。
- 即使经过亚组分析、敏感性分析或荟萃回归分析,仍存在显著异质性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 纳入的研究均为观察性研究,无随机对照试验。
- 即使经过亚组分析、敏感性分析或荟萃回归分析,仍存在显著异质性。
- 部分亚组可能缺乏生存获益。
- 需要进一步证据以更好地为肾衰竭患者的决策提供信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the survival benefit of transplantation versus dialysis for waitlisted kidney failure patients with a priori stratification. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Online databases MEDLINE, Ovid Embase, Web of Science, Cochrane Collection, and ClinicalTrials.gov were searched between database inception and 1 March 2021. INCLUSION CRITERIA: All comparative studies that assessed all cause mortality for transplantation versus dialysis in patients with kidney failure waitlisted for transplant surgery were included. Two independent reviewers extracted the data and assessed the risk of bias of included studies. Meta-analysis was done using the DerSimonian-Laird random effects model, with heterogeneity investigated by subgroup analyses, sensitivity analyses, and meta-regression. RESULTS: The search identified 48 observational studies with no randomised controlled trials (n=1 245 850 patients). In total, 92% (n=44/48) of studies reported a long term (at least one year) survival benefit associated with transplantation compared with dialysis. However, 11 of those studies identified stratums in which transplantation offered no statistically significant benefit over remaining on dialysis. In 18 studies suitable for meta-analysis, kidney transplantation showed a survival benefit (hazard ratio 0.45, 95% confidence interval 0.39 to 0.54; P<0.001), with significant heterogeneity even after subgroup/sensitivity analyses or meta-regression analysis. CONCLUSION: Kidney transplantation remains the superior treatment modality for most patients with kidney failure to reduce all cause mortality, but some subgroups may lack a survival benefit. Given the continued scarcity of donor organs, further evidence is needed to better inform decision making for patients with kidney failure. STUDY REGISTRATION: PROSPERO CRD42021247247.
引用
- Chaudhry D, Chaudhry A, Peracha J, et al. Survival for waitlisted kidney failure patients receiving transplantation versus remaining on waiting list: systematic review and meta-analysis. BMJ. 2022. PMID: 35232772. doi:10.1136/bmj-2021-068769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。